Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,421 to 1,440 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| FSC DPI vs FP DPI: Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period | 27 of 3,107 21 of 3,101 | 0.2 points -0.3 to 0.6 | 6,208 | NCT01462344 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old |
| FSC DPI vs FP DPI: serious adverse events | 56 of 3,107 54 of 3,101 | 0.1 points -0.6 to 0.7 | 6,208 | NCT01462344 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old |
| Febuxostat vs Allopurinol: deaths from any cause | 243 of 3,098 199 of 3,092 | 1.4 points 0.1 to 2.7 | 6,190 | NCT01101035 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) |
| Febuxostat vs Allopurinol: serious adverse events | 1,046 of 3,098 995 of 3,092 | 1.6 points -0.8 to 3.9 | 6,190 | NCT01101035 Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES) |
| Dalcetrapib vs Placebo: Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke or Hospitalization for New or Worsening Heart Failure | 321 of 3,071 346 of 3,076 | -0.8 points -2.4 to 0.8 | 6,147 | NCT02525939 Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS |
| Dalcetrapib vs Placebo: deaths from any cause | 182 of 3,071 180 of 3,076 | 0.1 points -1.1 to 1.3 | 6,147 | NCT02525939 Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS |
| Dalcetrapib vs Placebo: Composite of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, and Non-Fatal Stroke | 292 of 3,071 327 of 3,076 | -1.1 points -2.6 to 0.4 | 6,147 | NCT02525939 Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS |
| Dalcetrapib vs Placebo: Composite Endpoint of Cardiovascular Death, Resuscitated Cardiac Arrest, Non-Fatal Myocardial Infarction, Non-Fatal Stroke, Hospitalization for ACS (With Electrocardiogram Abnormalities) or Unanticipated Coronary Revascularization | 471 of 3,071 471 of 3,076 | 0.0 points -1.8 to 1.8 | 6,147 | NCT02525939 Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS |
| Dalcetrapib vs Placebo: serious adverse events | 900 of 3,071 923 of 3,076 | -0.7 points -3.0 to 1.6 | 6,147 | NCT02525939 Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS |
| RZV Group vs Placebo Group: Number of Participants With at Least One Related SAE From First Vaccination (Day 1) up to Study End (Duration of Approximately 2 Years) | 0 of 3,064 1 of 3,064 | -0.0 points -0.2 to 0.1 | 6,128 | NCT04869982 Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years |
| RZV Group vs Placebo Group: deaths from any cause | 13 of 3,064 11 of 3,064 | 0.1 points -0.3 to 0.4 | 6,128 | NCT04869982 Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years |
| RZV Group vs Placebo Group: serious adverse events | 90 of 3,064 94 of 3,064 | -0.1 points -1.0 to 0.7 | 6,128 | NCT04869982 Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years |
| Vericiguat vs Placebo: deaths from any cause | 392 of 3,053 455 of 3,052 | -2.1 points -3.8 to -0.3 | 6,105 | NCT05093933 A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) |
| Fluarix Quadrivalent 60 ug vs mRNA-1010 50 ug: deaths from any cause | 18 of 3,057 10 of 3,045 | 0.3 points -0.1 to 0.6 | 6,102 | NCT05415462 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults |
| Vericiguat vs Placebo: serious adverse events | 732 of 3,049 766 of 3,049 | -1.1 points -3.3 to 1.0 | 6,098 | NCT05093933 A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) |
| Expectant Management vs Elective Induction of Labor: Number of Infants With Neonatal Hypoxic-ischemic Encelphalopathy (Component of Primary Outcome) | 20 of 3,037 14 of 3,059 | 0.2 points -0.2 to 0.6 | 6,096 | NCT01990612 A Randomized Trial of Induction Versus Expectant Management |
| Expectant Management vs Elective Induction of Labor: Number of Participants With Cesarean Delivery | 674 of 3,037 569 of 3,059 | 3.6 points 1.6 to 5.6 | 6,096 | NCT01990612 A Randomized Trial of Induction Versus Expectant Management |
| Expectant Management vs Elective Induction of Labor: Number of Infants With Apgar Score ≤3 at 5 Minutes (Component of Primary Outcome) | 18 of 3,037 12 of 3,059 | 0.2 points -0.2 to 0.6 | 6,096 | NCT01990612 A Randomized Trial of Induction Versus Expectant Management |
| Expectant Management vs Elective Induction of Labor: Number of Participants Experiencing Hypertensive Disorder of Pregnancy | 427 of 3,037 277 of 3,059 | 5.0 points 3.4 to 6.6 | 6,096 | NCT01990612 A Randomized Trial of Induction Versus Expectant Management |
| Expectant Management vs Elective Induction of Labor: Participants Who Had Operative Vaginal Delivery | 258 of 3,037 222 of 3,059 | 1.2 points -0.1 to 2.6 | 6,096 | NCT01990612 A Randomized Trial of Induction Versus Expectant Management |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=72
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01462344-d2e8b2c9",
"title": "FSC DPI vs FP DPI: Number of Participants Experiencing Asthma-related Hospitalizations Over the 6-month Study Treatment Period",
"summary": "27 of 3107 against 21 of 3101; risk difference 0.2 points, 95% interval -0.3 to 0.6; NCT01462344, 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old",
"record": "/library/comparisons/NCT01462344-d2e8b2c9",
"nct_id": "NCT01462344",
"kind": "outcome",
"participants": 6208,
"risk_difference": {
"value": 0.0019180456858139457,
"lower": -0.0025556482419633745,
"upper": 0.006486125314267965
},
"group_1": "27 of 3,107",
"group_2": "21 of 3,101",
"difference": "0.2 points",
"interval": "-0.3 to 0.6",
"trial_title": "6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old"
},
{
"id": "NCT01462344-sae",
"title": "FSC DPI vs FP DPI: serious adverse events",
"summary": "56 of 3107 against 54 of 3101; risk difference 0.1 points, 95% interval -0.6 to 0.7; NCT01462344, 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old",
"record": "/library/comparisons/NCT01462344-sae",
"nct_id": "NCT01462344",
"kind": "serious-adverse-events",
"participants": 6208,
"risk_difference": {
"value": 0.0006100796829661449,
"lower": -0.006051589903612027,
"upper": 0.007282147742062084
},
"group_1": "56 of 3,107",
"group_2": "54 of 3,101",
"difference": "0.1 points",
"interval": "-0.6 to 0.7",
"trial_title": "6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=73",
"request_id": "0IM61jM8sB8hT7w2"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant